rosaria gangemi
rosaria gangemi
Affiliazione sconosciuta
Email verificata su
Citata da
Citata da
SOX2 Silencing in Glioblastoma Tumor‐Initiating Cells Causes Stop of Proliferation and Loss of Tumorigenicity
RMR Gangemi, F Griffero, D Marubbi, M Perera, MC Capra, P Malatesta, ...
Stem cells 27 (1), 40-48, 2009
Cancer stem cells: a new paradigm for understanding tumor growth and progression and drug resistance
R Gangemi, L Paleari, AM Orengo, A Cesario, L Chessa, S Ferrini, ...
Current medicinal chemistry 16 (14), 1688-1703, 2009
Synthesis and biological evaluation of novel pyrazole derivatives with anticancer activity
A Balbi, M Anzaldi, C Macciò, C Aiello, M Mazzei, R Gangemi, ...
European Journal of Medicinal Chemistry 46 (11), 5293-5309, 2011
Emx2 promotes symmetric cell divisions and a multipotential fate in precursors from the cerebral cortex
N Heins, F Cremisi, P Malatesta, RMR Gangemi, G Corte, J Price, ...
Molecular and Cellular Neuroscience 18 (5), 485-502, 2001
Anti-T12, an anti-CD6 monoclonal antibody, can activate human T lymphocytes.
RPL Gangemi RM, Swack JA, Gaviria DM
J immunol. 143 (8), 2439-47, 1989
The biology of uveal melanoma
A Amaro, R Gangemi, F Piaggio, G Angelini, G Barisione, S Ferrini, ...
Cancer and Metastasis Reviews 36 (1), 109-140, 2017
Taxol cytotoxicity on human leukemia cell lines is a function of their susceptibility to programmed cell death
RMR Gangemi, M Tiso, C Marchetti, AB Severi, M Fabbi
Cancer chemotherapy and pharmacology 36 (5), 385-392, 1995
Synthesis, antiproliferative and apoptotic activities of N-(6 (4)-indazolyl)-benzenesulfonamide derivatives as potential anticancer agents
N Abbassi, H Chicha, EM Rakib, A Hannioui, M Alaoui, A Hajjaji, ...
European journal of medicinal chemistry 57, 240-249, 2012
Mda-9/syntenin is expressed in uveal melanoma and correlates with metastatic progression
R Gangemi, V Mirisola, G Barisione, M Fabbi, A Brizzolara, F Lanza, ...
PloS one 7 (1), e29989, 2012
Regulatory genes controlling cell fate choice in embryonic and adult neural stem cells
RMR Gangemi, M Perera, G Corte
Journal of neurochemistry 89 (2), 286-306, 2004
Emx2 in adult neural precursor cells
RMR Gangemi, A Daga, D Marubbi, N Rosatto, MC Capra, G Corte
Mechanisms of development 109 (2), 323-329, 2001
Glioma immunotherapy by IL‐21 gene‐modified cells or by recombinant IL‐21 involves antibody responses
A Daga, AM Orengo, RMR Gangemi, D Marubbi, M Perera, A Comes, ...
International journal of cancer 121 (8), 1756-1763, 2007
Structural characterization of CD6: properties of two distinct epitopes involved in T cell activation.
RPL Swack JA, Gangemi RM, Rudd CE, Morimoto C, Schlossman SF
Mol Immunol. 26 (11), 1037-49, 1989
Glycosylated copper (II) ionophores as prodrugs for β-glucosidase activation in targeted cancer therapy
V Oliveri, M Viale, G Caron, C Aiello, R Gangemi, G Vecchio
Dalton Transactions 42 (6), 2023-2034, 2013
Targeting cancer-initiating cell drug-resistance: a roadmap to a new-generation of cancer therapies?
A Alama, AM Orengo, S Ferrini, R Gangemi
Drug Discovery Today 17 (9-10), 435-442, 2012
Spontaneous apoptosis in human thymocytes.
M Tiso, R Gangemi, AB Severi, S Pizzolitto, M Fabbi, A Risso
The American journal of pathology 147 (2), 434, 1995
New perspectives in glioma immunotherapy
A Daga, C Bottino, R Castriconi, R Gangemi, S Ferrini
Current pharmaceutical design 17 (23), 2439-2467, 2011
Synthesis and antitumor activity of some substituted indazole derivatives
N Abbassi, EM Rakib, H Chicha, L Bouissane, A Hannioui, C Aiello, ...
Archiv der pharmazie 347 (6), 423-431, 2014
Effects of Emx2 inactivation on the gene expression profile of neural precursors
RMR Gangemi, A Daga, L Muzio, D Marubbi, S Cocozza, M Perera, ...
European Journal of Neuroscience 23 (2), 325-334, 2006
Potential role of soluble c-Met as a new candidate biomarker of metastatic uveal melanoma
G Barisione, M Fabbi, A Gino, P Queirolo, L Orgiano, L Spano, V Picasso, ...
JAMA ophthalmology 133 (9), 1013-1021, 2015
Il sistema al momento non può eseguire l'operazione. Riprova più tardi.
Articoli 1–20